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Pharmacotherapy of Preterm Labor
Britt E. Travis, Pharm.D., and Jill M. McCullough, Pharm.D.
Preterm labor is defined as the onset of uterine contractions in a woman who
has completed less than 37 weeks of pregnancy. It may be due to maternal,
placental, fetal, or idiopathic causes, and it is associated with a number of risk
factors. Nondrug measures such as bedrest and hydration have been used
alone or in combination with drug therapy to treat the disorder. Pharmacologic
(tocolytic) agents include ethanol, progesterone, indomethacin, nifedipine, 13-
adrenergic agonists, and magnesium salts. The three most commonly used
drugs are ritodrine, terbutaline, and magnesium.
(Pharmacotherapy 1993;13(1 ):28-36)
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Labor is usually defined as the onset of uterine
contractions accompanied by dilation and
effacement of the cervix.1, 2 Determining its onset
is complex, and is based on the pattern of uterine
contractions, the status of the cervix including
degree of effacement and amount of dilation, and
whether the uterine membranes are ruptured or
unruptured.v " Labor is considered to be preterm if
it occurs in a woman who has completed less than
37 weeks of pregnancy (dated from the first day of
her last menstrual period).': 5 Despite increased
knowledge of its causes and improved prenatal
care, the number of women experiencing preterm
labor has remained stable in the United States
over the last three decades; approximately 9% of
all infants are born prematurely."
Two-thirds of neonatal morbidity and mortality
not related to congenital defects result from the
complications of preterm birth." Advances in
perinatology have allowed for the survival of most
infants born beyond 28 weeks' gestation, but
almost 10% of these infants suffer from a
permanent nongenetic handicap.' In addition, the
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cost of caring for a low-birth-weight infant in a
neonatal intensive care unit (NICU) can be
astronomical"; it is estimated to range from
$14,000-30,000. 7 Thus, prevention or post-
ponement of preterm birth to allow for maximum
fetal development in utero is a major priority for
obstetricians and perinatologists.
Pathogenesis of Preterm Labor
In approximately 50% of cases preterm labor
has an idiopathic etioloqy." It may also be due to
maternal, fetal, or placental factors; respectively,
these are disease (e.g., pregnancy-induced
hypertension, infection) and structural defects of
th~ uterus or cervix; multiple gestations (e.g.,
twins, triplets) and abnormalities of the amniotic
fluid (polyhydramnios, oligohydramnios); and
placenta previa and abruptio placentae.' In
addition, various demographic, behavioral, and
medical factors may place a woman at risk," such
as inadequate prenatal care, a history of preterm
labor or abortions, the use of alcohol or other
addictive drugs, age «17 or >35 yrs), race, and
socioeconomic status.': 6
Management - An Overview
Before instituting any intervention for a woman
with documented preterm labor, the risks and
benefits of abating labor must be assessed. This
requires evaluating fetal lung maturity, the status of
the fetus (e.g., estimated weight, presence of fetal
distress or anomalies, etc.), and the stage of
labor.' Uterine membrane status is also important.
Patients with ruptured membranes, with or without
uterine contractions, are at an increased risk of
infection and it is less likely that their delivery can
be delayed." The use of tocolytic therapy to
prevent preterm birth in patients with ruptured
membranes is controversial. Conversely,
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tocolytics have been studied extensively in patients
with intact membranes, and they may successfully
delay delivery in many of these women."
Depending on the status of the mother and fetus,
the goal of tocolytic therapy may be to prolong
gestation as long as possible, or simply to delay
delivery for 48-72 hours (allowing for transport to
an NICU).
Tocolytics are relatively contraindicated in
women with mild chronic hypertension,
hyperthyroidism, cardiac disease, or uncontrolled
diabetes.8,9 These medical conditions may be
exacerbated by the drugs, namely, [3ragonists.
Other relative contraindications are mild abruptio
placentae, stable placenta previa, and fetal
distress. Absolute contraindications include severe
pregnancy-induced hypertension, severe abruptio
placentae or bleeding from any cause,
chorioamnionitis, severe fetal growth retardation,
and fetal death.9
Nondrug measures may be used, either as the
only treatment or in addition to tocolytics. Bedrest
is often recommended, although its effectiveness
as sole therapy has not been substantiated.'
Hydration has also been used, but its efficacy in
this setting has yet to be proved.' Caution must be
used when hydrating pregnant patients, because
overhydration may increase the risk of adverse
effects due to tocolytic drugs, namely pulmonary
edema.'
Miscellaneous Agents
Various mechanisms of action have been
proposed to account for the effectiveness of
tocolytic druqs.' Some agents act directly on the
myometrial cells to cause relaxation of the uterine
muscle. Others decrease the amount of calcium
available in myometrial cells, through a complex
series of biochemical reactions, to produce
relaxation.
Ethanol, once an agent of choice for the
treatment of preterm labor, inhibits oxytocin
secretion from the pituitary qland.? Although it is
sometimes effective, adverse effects such as
maternal intoxication and a high frequency of
respiratory depression in neonates are
disadvantages to its use .' Therefore, more
effective drugs have replaced ethanol as first-line
therapy to delay delivery.
Progesterone affects myometrial gap junctions,
which conduct electrical impulses through
myometrial tissue. The result is a decrease in
uterine muscle excitability." Because this effect
develops over an extended period of time (up to 24
hrs), progesterone is often ineffective in treating
preterm labor.
Isoxsuprine was the first [32-agonist to be used in
the United States to treat preterm labor." A few
reports demonstrated some efficacy,":" but only
one was a randomized, controlled tr ial.!'
Isoxsuprine is seldom used because other [3-2
agonists that have been more extensively studied
are available, including ritodrine, which has
received approval from the Food and Drug
Administration (FDA).
Indomethacin inhibits the synthesis of
prostaglandins, leading to decreases in free
calcium levels and in myometrial muscle
contraction.:"" Limited numbers of controlled
studies'":" reported some success in treating
preterm labor with indomethacin, prolonging
gestation for at least 24 hours in most cases and
up to 12 weeks in one"; however, another group
failed to demonstrate any significant gain in weeks
of gestation. 20 The major side effect of
indomethacin is gastrointestinal upset, but it rarely
warrants discontinuation of treatrnent.l":" Isolated
case reports 23. 24 suggested that the drug may
cause premature closing of the ductus arteriosus in
the fetus, possibly leading to primary pulmonary
hypertension in the newborn. However, the
complications of prematurity (infection, respiratory
distress syndrome, etc.) make it difficult to
determine if indomethacin is directly responsible.
In addition, its effects on platelet aggregation and
its ability to mask temperature elevations could
complicate pregnancy if severe bleeding occurs
during delivery or if infection is present." These
concerns have limited the agent's use for the
treatment of preterm labor.
Nifedipine shows some promise as a
tocotytlc."?' It inhibits the movement of calcium
into smooth muscle, thereby blocking the
interaction between contractile proteins and
preventing myometrial contractions." Dosages
typically are 20 mg 3 times/day. Treatment for as
few as 3 days resulted in a delay of delivery for a
mean of 14 days in one report" and 36.3 days in
another." Side effects are minimal, the most
common being facial flushing; headache and
increased pulse rate have also been reported." 28, 29
Due to its apparent efficacy and lack of significant
side effects, nifedipine may be valuable in this
setting, but larger trials are necessary to define its
role.
Ritodrine
Ritodrine hydrochloride, an adrenergic agonist
with selective [32-receptor activity, is currently the
only FDA-approved agent for the treatment of
preterm labor.32,33 It binds to [32-receptors located
on the outer surface of the myometrium, triggering
the conversion of adenosine 5' -triphosphate to
cyclic adenosine 3',5'-monophosphate (cAMP).34
As a result, the activity of the sodium-potassium
pump is increased, creating a gradient that
accelerates the rate of sodium and calcium
exchange, which leads to an increase in the
amount of calcium that is pumped out of the
myometrial cells. Decreased intracellular calcium
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causes a decrease in the combining of actin and
myosin, and a decrease in muscle contractions.
The result is relaxation of myometrial tissue."
Ritodrine may also act on the trophoblast, a
structure that eventually becomes part of the
placenta. In this tissue, ~2-agonists increase
cAMP, leading to increased production of placental
proqesterone." Progesterone acts to decrease the
number of myometrial gap junctions and thus
inhibits uterine contractions."
Ritodrine can be administered orally or by
intravenous infusion. Intramuscular injection is
undesirable due to difficulties in dose titration and
pain on injection." Subcutaneous injection is not
recommended because the volume of fluid
necessary to deliver a dose cannot be given
subcutaneously. Oral ritodrine undergoes
significant first-pass metabolism, which results in
bioavailability of approximately 30%.33,37
The manufacturer recommends an initial
intravenous infusion of 100 uq/rninute, with
increases of 50 ).lg/minute every 10 minutes to a
maximum of 350 ).lg/minute. The rate should be
increased until contractions cease, and then
maintained for at least 12 hours." A modified
protocol that aims to minimize side effects and fluid
overload is 50 ).lg/minute initially, with increases of
50 ).lg/minute every 20 minutes to a maximum of
350 ).lg/minute.35 Once contractions have stopped,
the infusion rate is maintained for 1 hour and then
is decreased by 50 ).lg/minute every 30 minutes to
the lowest rate that inhibits uterine activity (no
lower than 50 ).lg/min). This maintenance rate is
continued for 12 hours. If labor recurs, the entire
protocol is repeated.
Dosage adjustments should be made according
to maternal effects as well." If the maternal heart
rate is greater than 140 beats/minute, the dosage
of ritodrine should not be increased further; if the
patient is symptomatic the dosage should be
decreased.
Ritodrine solutions are prepared by diluting 150
mg of drug in 500 ml 5% dextrose for a final
concentration of 0.3 mg/ml.33 Normal saline may
be used when treating diabetic patients, and more
concentrated solutions may be prepared if fluid
restriction is necessary."
Oral ritodrine is usually started 30 minutes
before the infusion is discontinued.>:" The initial
dosage is 10 mg every 2-4 hours for 24 hours, and
then 10-20 mg every 4-6 hours until ritodrine is no
longer needed.': 33, 34 During the initial 24 hours,
the more frequent schedule is often employed."
Adjustments are guided further by patient response
and adverse effects. The maximum recommended
daily dose is 120 mg.33
Ritodrine is relatively specific for ~2-receptors;
however, receptors in the heart, bronchi, and other
tissues are structurally similar to those in the
uterus, thus increasing the chance of adverse
effects. As a result, maternal heart rate and
contractility increase when the drug is
adrninistered.w " This effect can be additive to the
already volume-overloaded, hyperdynamic cardiac
state of a pregnant woman."
Intravenous ritodrine was associated with
palpitations in one-third of all patients studied in
the United States. 34 Other reported cardio-
pulmonary events with this and other ~-agonists
are hypotension." chest pain.": 40 shortness of
br eath;": 40 angina pectorts." myocardial
ischemia," and cardiac arrhythmias."
Pulmonary edema has been associated with the
use of ~-agonists,35, 42-46 perhaps due to iatrogenic
fluid overload or to fluid retention secondary to
decreased urinary sodium and water loss caused
by the drugs. Multiple gestation appears to be a
risk factor for the development of pulmonary
edema."-" The concomitant use of cortico-
steroids to promote fetal lung maturity also is
proposed as a risk factor, although pulmonary
edema has been reported in patients receiving ~­
agonists without simultaneous steroid therapy.
Moreover, the corticosteroids most commonly used
in preterm labor (betamethasone, dexamethasone)
have little if any mineralocorticoid activity.
Due to the effect of ~2-agonists on
glycogenolysis and gluconeogenesis in the liver
and skeletal muscle, maternal serum glucose
concentrations increase with ritodrine admin-
istration." This increase occurs early in therapy
and may resolve without intervention or gradually
decrease toward normal with continued
treatment. 38,47 Diabetic patients may have a
significantly greater increase than nondiabetic
patients and thus they are at risk of developing
diabetic ketoacidosis; insulin may be required to
control their blood glucose.35, 38 Blood glucose
levels should be monitored in all patients receiving
ritodrine," with appropriate interventions initiated
as needed.
Changes in serum levels of triglycerides, free
fatty acids, and other lipids may occur with
ritodrine, but these effects usually resolve within 24
hours." Transient hypokalemia is frequent, but
replacement therapy is rarely warranted because
total-body potassium usually remains normal."
Nausea, headache, nervousness, and anxiety can
also OCCUr.34
Ritodrine crosses the placenta." Fetal adverse
effects are similar to those seen in the mother, but
may occur less often because fetal drug
concentrations are usually lower than maternal
levels.48 A mean maternal:fetal ratio of serum
ritodrine was reported to be 1.17 ± 0.48.49
Fetal heart rate may increase or decrease, but
the change is usually not clinically significant. 50
Neonatal hypoglycemia may result from maternal
hyperglycemia and hypertnsutlnernla." The
hypoglycemia may be most pronounced if ritodrine
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is discontinued shortly before delivery. However,
one report concluded that no difference in blood
glucose existed between infants born to mothers
who had received long-term ritodrine therapy and
control infants." Fetal acid-base status may be
affected because maternal ritodrine-induced
lipolysis may cause substances such as lactate
and pyruvate to cross the placenta and decrease
the pH of the fetal circulatio n.s? Neurologic
deficiencies do not appear to occur at a higher rate
in infants born to ritodrine-treated mothers than in
the general population."
Terbutaline
Terbutaline sulfate, a selective 132-adrenergic
agonist, has the same mechanism of action as
ritodrine. It can be administered orally,
intravenously, and subcutaneously.
After oral administration, the drug undergoes
significant first-pass and gut metabolism,52-54 and
has resultant bioavailability ranging from
10-15%.53 Absorption is impaired in the presence
of food." A few small pharmacokinetic studies
have been performed in pregnant women.55, 56 The
mean half-life of terbutaline in a small group was
3.7 hours before delivery, compared with 5.3 hours
postpartum." The drug has increased clearance in
pregnant patients.55, 57
Numerous dosages have been employed to treat
preterm labor. Intravenous infusions are usually
initiated at 5-10 flg/minute and the rate is
increased gradually every 10-15 minutes to a
maximum of 80 flg/minute.58-60 Some clinicians
prefer to initiate the infusion at a lower rate (2.5
uq/rnin] and make adjustments over a longer
interval (every 20 min)." They also favor tapering
the infusion rate every 20 minutes to the lowest
effective dose once contractions have been
adequately controlled." These guidelines have
been proposed to try to reduce the risk of adverse
reactions and fluid overload. Terbutaline can be
diluted in 5% dextrose or 0.9% sodium chloride for
diabetic patients; concentrations of 20-50 fl9/ml
have been used for the continuous infusion.59,61
Oral terbutaline is usually initiated 12 to 24 hours
after an intravenous infusion is started, provided
that contractions have been controlled during that
time.58, 61 The dosage varies, ranging from 5 mg 3
times/day to 2.5-5 mg every 4 hours.w 60, 61
Adjustments are made based on patient response
and side effects.
Subcutaneous injections may be administered
after intravenous infusions prior to switching to oral
treatrnent.?" or as an initial treatment before
initiating long-term oral therapy." When used as a
transitional treatment, the dosage is 250 fl9 every
4-6 hours.60,63 As an initial therapy, 250 fl9 every
30-60 minutes effectively inhibits uterine
contractions.62 The maximum dose is 1 rnq."
Continuous subcutaneous infusions using a
modified miniature pump (terbutaline pump
therapy) have also been used to treat preterm
labor. Tocolytic failure is often associated with
intravenous or oral treatment, and is thought to be
due to 132-receptor down-requlation." Lower total
daily subcutaneous doses may prevent the down-
regulation and thus tocolytic failure. It is also
believed that a basal infusion can control uterine
irritability, therefore preventing the development of
uterine contractions." Effective total daily doses of
terbutaline using this mode of administration range
from 2-4 mg.64, 65
Preterm labor was treated successfully in nine
outpatients using a subcutaneous infusion pump
containing terbutaline 3 mg in a 3-ml reservoir."
Patients received an initial infusion of 50 fl9/hour,
with boluses of 240 fl9 as needed during periods of
increased uterine activity. Delivery was delayed an
average of 9.2 ± 4.3 weeks, and only one patient
experienced tocolytic failure, requiring stabilization
with intravenous magnesium sulfate. She was
then discharged with terbutaline pump therapy, and
delivered during the thirty-eighth week ot
pregnancy.
The advantage of the outpatient subcutaneous
pump is threefold: the total daily dose of
terbutaline is much lower than typical daily
intravenous or oral doses; it does not require large
volumes of fluid, as intravenous infusions do,
which reduces the risk of fluid overload; and
patients do not have to be hospitalized to receive
therapy." However, terbutaline pump therapy is
more expensive than oral tocolysis and requires
intensive home monitoring. Comparative efficacy
studies of terbutaline pump therapy and
intravenous or oral regimens have not been
published to date.
Terbutaline, like ritodrine, is not specific for
uterine muscle. During intravenous infusions, the
most common adverse effects are tachycardia,
tremor, palpitations, shortness of breath, and
dizziness.P 58, 60, 63 Adverse cardiovascular effects
caused termination of therapy in up to 10% of
patients." As with ritodrine, patients must be
monitored closely for the development of cardiac
arrhythmias or pulmonary edema.
Moderate increases in serum glucose
concentrations have been noted during terbutaline
infusions. The concentration generally remains
elevated throughout the infusion, but returns
toward normal after treatment is stopped. A
corresponding increase in serum insulin is also
seen. 66 Therefore, as with ritodrine therapy,
caution should be used when administering
terbutaline to pregnant patients with diabetes, and
serum glucose levels should be monitored in all
patients.
Transient hypokalemia occurs in some patients
receiving terbutaline, with little effect on serum
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sodium, creatinine, or phosphorus. 42 , 62, 66 The
hypokalemia is most likely due to intracellular
movement of potassium in response to increased
insulin secretion. A significant increase in serum
lactate has also been reported." Some patients
experience vomiting during drug infusion, which
may contribute to the metabolic changes." 63
Subcutaneous administration causes fewer
adverse reactions than intravenous and oral
therapy because lower total daily doses are used.
In one report, a total of 394 patient days were
reviewed in nine patients receiving subcutaneous
terbutaline pump therapy." No cardiac or
electrolyte abnormalities were reported. The mean
maternal pulse rate was 88 ± 12 beats/minute.
However, bolus injections did cause transient
increases in maternal pulse rate. In a larger chart
review of 70 patients," one patient experienced
anxiousness and shortness of breath after an
intermittent subcutaneous dose, which resolved on
discontinuation of therapy.
Terbutaline crosses the placenta, and
therapeutic levels can be achieved in the
tetus ." In a study of 14 healthy pregnant
women, the average umbilical cord blood
concentration:maternal vein concentration was
0.36 ± 0.15 after a single injection of 250 Ilg. 67
Fetal tachycardia may occur during intravenous
intusions." Infants born to terbutaline-treated
mothers appear to be developmentally and
neurologically equivalent to those who were not
exposed to the drug in utero.
Fetal glucose levels tend to parallel maternal
levels. 68 Some infants may have a high insulin
level at birth, but it does not appear to correlate
with terbutaline administration." Newborns also
may experience hypoglycemia, especially if the
mother received combination terbutaline-steroid
therapy."
Magnesium
Magn~sium inhibits uterine contractions by
decreasing the release of acetylcholine at the
neuromuscular junction, thus decreasing the
amplitude of electrical signals in myometrial cells."
Increased intracellular magnesium also leads to
increased cAMP concentrations, resulting in an
increase in the amount of calcium that is pumped
out of the myometrial celts."? In addition,
magnesium may prevent the entry of calcium into
myometrial cells.' The interaction of contractile
proteins, and therefore muscle contraction, does
not occur in the presence of low intracellular
calcium.
Magnesium may be administered by the
intravenous or oral route. As with the 132-agonists,
numerous dosing protocols exist for the treatment
of preterm labor. Intravenous magnesium sulfate
is generally given as a loading dose of 4-6 g over
20 minutes, followed by a maintenance infusion of
2-3 g/hour and continued for 12-24 hours if it is
successful.':" Maintenance infusions as high as 4
g/hour have been administered in some cases."
The loading dose is prepared by diluting
magnesium sulfate 4 g in 250 ml 5% dextrose or
0.9% sodium chloride solution.' The maintenance
solution contains 20-40 g in 500-1000 ml diluent."
Serum magnesium levels should be measured
within 6 hours of the start of the intusion."
Tocolytic success has been reported with serum
levels of 5.5-7.5 mg/dl (4.5-6.25 mEq/L).72
Once contractions have stopped, rnaqnasiurn
oxide or gluconate 250-500 mg is administered
orally every 3 hours.v " Due to erratic absorption
of these salts and the potential for significant
diarrhea, some clinicians favor the use of an oral
132-agonist after intravenous rnaqnesium.": 73, 74
Another protocol employs the same intravenous
and oral dosing schemes, but also stresses the
importance of monitoring fluid status, respiratory
function, and reflexes throughout treatment."
Fewer adverse effects occur with magnesium
than with 132-agonists, and can be predicted based
on serum magnesium levels. Reflexes are lost at
levels of 12 mg/dl (10 mEq/L), respiratory
depression can occur at 14-18 mg/dl (12-15
mEq/L), and cardiac arrest is possible at levels
above 18 mg/dl (15 mEq/L).1
According to a retrospective review, only 24 of
355 patients treated with intravenous magnesium
sulfate experienced adverse effects, and only 7 of
them had to discontinue treatment." The most
common adverse effects were nausea and/or
flushing, which were similar to those reported in
another study." Chest .pain, chest tightness,
drowsiness, and blurred vision were also reported.
Four p~tients experienced pulmonary edema,
necessitating discontinuation of therapy. General
muscle weakness, respiratory depression, and
hypotension led to the discontinuation of a
magnesium infusion in one report." Diarrhea has
been reported with oral magnesium and may
prevent its use." Metabolic effects, such as
hypokalemia and hyperglycemia, are rare, and
thus magnesium may be a safer agent than the 132-
agonists for the management of preterm labor in
diabetic patients.
Magnesium freely crosses the placenta. Infants
with defective bone formation and rickets have
been born to women treated with long-term
intravenous magnesium sulfate tocolysis.": 79 In
one report the abnormality resolved postnatany."
One group observed no significant changes in fetal
tone, amniotic fluid volume, or body movements in
infants born to mothers treated with magnesium
sulfate." They did, however, note a decrease in
fetal heart rate.
Comparative Trials
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Numerous clinical trials have been conducted to
assess the efficacy of the various drugs in the
treatment of preterm labor. The data generated by
these trials are often difficult to interpret and
compare due to differences in study design,
definitions of preterm labor, inclusion and exclusion
criteria, routes of drug administration, and the
dosages of agents. The following is a review of
some of the randomized comparative trials that
were conducted with ritodrine, terbutaline, and
magnesium. They were similar with respect to
inclusion and exclusion criteria, drug dosages, and
routes of administration, which should assist the
reader in understanding how the agents compare
to one another.
A prospective, randomized, double-blind trial
compared the intravenous and oral forms of
ritodrine and terbutaline." All patients received an
intravenous infusion of either ritodrine 50-350
Ilg/minute, titrated to the lowest effective dosage,
or terbutaline 2.5-17.5 Ilg/minute, titrated to the
lowest effective dosage, for 12 hours. Patients
with intact membranes were then switched to oral
therapy with their respective drug-ritodrine 20 mg
or terbutaline 5 mg every 4 hours for 5 days. Both
agents effectively suppressed uterine contractions
during intravenous infusion. However, patients
who received oral ritodrine experienced
significantly more episodes of recurrent preterm
labor (12/23 patients) than those receiving oral
terbutaline (1/19; p<0.001). In the former group, 8
of the 12 patients experiencing recurrent labor
delivered during the initial hospitalization, whereas
15 of the 23 without a recurrence were discharged
without delivering, and 6 of them did not deliver
until after 36 weeks of pregnancy. The patient who
experienced recurrent preterm labor while
receiving oral terbutaline did not deliver as a result
of that episode. Twelve of the remaining 19
patients treated with terbutaline did not deliver until
after 36 weeks of pregnancy. Adverse effects
during the infusion period were comparable
between groups. Patients receiving ritodrine
suffered more tachycardia, and those receiving
terbutaline more often experienced hyperglycemia.
These results suggest that both agents are equally
effective when given intravenously, but terbutaline
may be a better choice for oral therapy to prevent
recurrent preterm labor.
Patients in preterm labor with intact membranes
were randomized to receive an intravenous loading
dose of magnesium sulfate 4 g, then 2 g/hour for 2
hours and 1 g/hour for 22 hours, or terbutaline 250
Ilg loading dose, then 10-25 Ilg/minute, titrated to
the lowest effective dosage, for 22 hours." Both
groups of patients also received a single 5-mg oral
dose of terbutaline 20 hours after the magnesium
or terbutaline loading dose. The success rate,
defined as delay of delivery for at least 24 hours,
was similar for both agents: 64% (9/14) for
magnesium, and 67% (10/15) for terbutaline. Fifty-
seven percent of patients receiving magnesium
and 53% receiving terbutaline were able to
postpone delivery until after 37 weeks' gestation.
There were no clinically significant side effects with
the magnesium sulfate infusion. However, five
patients in the terbutaline group discontinued
treatment due to chest pain, shortness of breath, or
nausea and vomiting. Thus, although both agents
had similar success rates, magnesium sulfate was
favored as a first-line agent due to the lack of
adverse effects during the infusion period. It is
difficult to interpret the results of this study fully,
however, because the single oral dose of
terbutaline does not reflect what is currently
common practice (i.e., oral therapy until 37 wks'
gestation).
In another study, seventy patients were
randomized to receive an infusion of ritodrine
100-350 Ilg/minute, titrated to the lowest effective
dosage, for 12 hours or magnesium sulfate 4 g
loading dose, followed by 2 g/hour continuous
infusion, titrated to achieve levels of 6-8 mg/dl, for
12 hours." Participants who failed to respond to
one agent were treated with the other agent, and
those who failed both drugs were withdrawn from
the study. Those who responded to either drug
were switched to oral ritodrine 10 mg every 2 hours
for 24 hours, then 10 mg every 4 hours until 37
weeks' gestation. Patients without insurance
received oral terbutaline 5 mg every 4-6 hours
until 37 weeks' gestation due to the lower cost; this
did not appear to have any impact on the outcome
of the study. Thirty-six patients received ritodrine
first, and three received ritodrine after magnesium
sulfate failed to stop labor. Thirty-four patients
received magnesium sulfate first, and six received
magnesium sulfate after ritodrine failed to stop
labor.
As a first- or second-line agent, ritodrine
successfully delayed labor for at least 72 hours in
31 (79%) of 39 patients, and for 1 week or more in
28 (72%) of 39 patients. Magnesium sulfate as a
first- or second-line agent delayed labor for at least
72 hours in 35 (88%) of 40 patients, and for 1 week
or more in 30 (75%) of 40 patients. No information
about delaying delivery until 37 weeks' of gestation
was reported. The time required to achieve uterine
quiescence was significantly shorter for patients
receiving ritodrine (mean 1.56 hrs vs 3.3 hrs for
patients receiving magnesium sulfate; p<0.05).
However, patients receiving magnesium sulfate did
not experience any progressive cervical changes
during this time period. The frequency of adverse
effects was similar for both groups (38 reports in
the ritodrine group vs 33 reports in the magnesium
sulfate group). Patients receiving ritodrine
experienced hypokalemia, hyperglycemia, nausea,
and cardiac side effects, whereas the patients
receiving magnesium sulfate experienced lethargy,
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nausea, dry mouth, dizziness, and nystagmus.
Two patients receiving ritodrine had to discontinue
therapy due to tachycardia, and two patients
receiving magnesium sulfate required a decrease
in dosage due to lethargy, but did not have to
discontinue treatment.
These results suggest that ritodrine may be a
better choice for the treatment of preterm labor due
to its more rapid suppression of uterine activity,
which can help to relieve some of the anxiety
associated with the disorder. Magnesium sulfate
may also be considered a drug of choice because
it usually does not cause serious cardiac side
effects. Also, serum magnesium levels can be
used in making dosage adjustments, due to the
close relationship between serum levels and
tocolysis.
In a prospective trial, 50 patients were
randomized to receive either oral terbutaline 2.5-5
mg every 3-4 hours, or oral magnesium oxide 200
mg every 3-4 hours after successful intravenous
tocolysis." Patients continued oral tocolysis until
the thirty-sixth week of gestation. Estimated
gestational ages at entry and delivery were
comparable between the two groups. Adverse
effects of terbutaline included palpitations,
tachycardia, shaking, and nervousness. The
primary adverse effects of magnesium oxide were
diarrhea, nausea, and vomiting. Recurrence of
preterm labor was similar for both drugs: 11
episodes in patients receiving terbutaline, 13
episodes in patients receiving magnesium oxide.
Magnesium oxide may be a rational choice for
long-term oral tocolysis because it is less
expensive than oral terbutaline, but it may cause
diarrhea. One must interpret the results of this
study cautiously because the initial intravenous
tocolytic therapy, which was not reported, may
have affected the outcome.
In another randomized trial, 45 patients received
ritodrine 100-350 uq/rninute, 40 received
terbutaline 20-70 /-lg/minute, and 46 received
magnesium 1.5-3.5 g/hour after a 4-g loading
dose. 83 All agents were administered as a
continuous infusion that was continued for 12
hours after contractions had stopped. Patients
who failed to respond or could not tolerate the
adverse effects of one class of agent were
switched to the other class. Both classes were
equally effective in delaying delivery for at least 48
hours, although more patients treated with
magnesium sulfate experienced persistent
contractions. The number of days gained in utero
was not significantly different between the 13-
agonists and magnesium sulfate (ritodrine 43 ± 25
days, terbutaline 55 ± 17 days, magnesium 38 ± 27
days).
It is difficult to interpret these results, however,
because each patient was switched to oral
terbutaline 2.5 mg every 4 hours at the end of the
infusion. Successful outcomes may have been the
result of the long-term oral treatment rather than
the initial tocolytic agent. As in other trials, the 13-
agonists caused more adverse effects, mainly
cardiovascular. This led to a number of treatment
failures because patients could not tolerate
effective dosages of ritodrine or terbutaline.
Conclusion
In general, patients experiencing preterm labor
are initially stabilized with an intravenous agent,
and then treated until 37 weeks of gestatiop with
an oral tocolytic drug. Although few data support
long-term oral tocolytic therapy (i.e., until 37 wks of
pregnancy), it is a common practice.
In otherwise healthy patients, intravenous
magnesium sulfate is considered to be the drug of
choice in treating preterm labor. It is easy to
administer and has fewer adverse effects than
ritodrine or terbutaline. If the contractions have
been inhibited for 12-24 hours with intravenous
magnesium sulfate, the patient is given art oral
tocolytic. Terbutaline is usually the oral agent of
choice because it is cheap and appears to be as
effective as ritodrine. The efficacy of oral
magnesium oxide and gluconate has not been
established. If the patient fails to respond to
intravenous magnesium sulfate, intravenous
ritodrine is administered according to the
manufacturer's quidelines, followed by oral
terbutaline.
Cardiac disease is an absolute contraindication
to the use of ritodrine and terbutaline due to the
cardiac side effects of these drugs. Thus,
magnesium sulfate is the' agent of choice in these
patients. It is also preferred for diabetic patients.
However, the effects of ritodrine and terbutaline on
serum glucose can be managed with insulin.
Diabetes is therefore considered a relative
contraindication to treatment with the I3ragonists.
Patients who have failed standard therapies at
least once may be candidates for subcutaneous
terbutaline pump therapy. However, this method is
more expensive than oral terbutaline, and requires
significant patient involvement. If a patient fails
subcutaneous terbutaline pump therapy,
intravenous magnesium sulfate followed by oral
terbutaline may be tried again. It is thought that
treatment with magnesium allows for the
regeneration of 132-receptors, and subsequent
successful tocolysis with an oral 132-agonist.
Despite the development of effective tocolytic
drugs and an increase in their use, preterm labor is
still a significant health problem in the United
States. Thus, in addition to the search for new
agents that are effective, safer, and easier to use,
efforts must be focused on preventing preterm
labor. Adequate prenatal care must be made
available to all women, and those at risk for
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preterm labor should receive additional attention.
Finally, all health care professionals should be
educated about preterm labor and their role in
preventing and treating this unfortunate
complication of pregnancy.
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